GlassScriptPhysician profile
John T Ruxer
NPI 1205078987
$32,849.93
in general payments reported to CMS, 2019-2025
37 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what 79% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $2,413 · 2021: $6,607 · 2022: $7,653 · 2023: $10K · 2024: $3,025 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,388 · Food and Beverage: $5,674 · Travel and Lodging: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,387.50 |
| Food and Beverage | $5,673.68 |
| Travel and Lodging | $337.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24,353.98 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Medtronic, INC. | $2,361.13 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Abbott Laboratories | $1,114.74 | 2021-2025 | Proclaim, Octrode, Eterna |
| Collegium Pharmaceutical, INC. | $1,056.72 | 2019-2025 | Belbuca, Xtampza |
| Si-Bone, INC. | $688.46 | 2020-2025 | |
| Amgen INC. | $474.18 | 2019-2025 | Evenity, Prolia, Prolia |
| Horizon Therapeutics Plc | $451.48 | 2019-2022 | |
| Nevro Corp. | $301.70 | 2019-2024 | Senza |
| Pfizer INC. | $245.35 | 2019-2023 | |
| Globus Medical, INC. | $231.39 | 2025 | Senza |
| Abbvie INC. | $190.82 | 2021-2025 | Ubrelvy |
| Curonix LLC | $156.01 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceutical Holding Company LTD. | $154.31 | 2022 | |
| Scilex Pharmaceuticals INC. | $141.47 | 2019-2023 | Ztlido |
| Medtronic USA, INC. | $88.05 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $86.79 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $78.48 | 2022-2023 | Euflexxa |
| Lilly USA, LLC | $74.79 | 2020-2022 | |
| Zyla Life Sciences, INC. | $65.48 | 2019-2020 | |
| Averitas Pharma INC. | $60.16 | 2025 | Qutenza |
| Biodelivery Sciences International, INC. | $57.96 | 2021 | |
| Spinal Simplicity, LLC | $49.91 | 2022-2023 | Ha Minuteman G3-R |
| Daiichi Sankyo INC. | $49.09 | 2019 | |
| Hikma Pharmaceuticals USA | $47.30 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $37.63 | 2022 | |
| Assertio Therapeutics, INC. | $29.04 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.61 | 2019 | |
| Stryker Corporation | $23.01 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.32 | 2025 | |
| Axsome Therapeutics, INC. | $20.55 | 2025 | Symbravo |
| Ibsa Pharma INC. | $15.65 | 2023 | Tirosint, Licart |
| Akcea Therapeutics, INC. | $15.38 | 2019 | |
| Mdd US Operations, LLC | $14.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2022 | |
| Allergan, INC. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ruxer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.